{"name":"Attenuon","slug":"attenuon","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ATN-224","genericName":"ATN-224","slug":"atn-224","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"ATN-224","genericName":"ATN-224","slug":"atn-224","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxOdld4dU9fMC00TWVGdDhmbFlYNGdxVkdiZjk2VWhQRjdzUFlsQ2hDdUFiN3Nmb0dWMUlfRjFieVpzT3FGOFJBWXJtbjNILXR1LXFhNC1jUEd3SkhGWDk1cy01OFIxOEptUm5XT0ZOQkRFNkxTUmxtTDA5OGN1ZUJEdDNZSkpDVzJIelAzU2xxcVNWSXl2bFZIOUpCTTRDeTBvME4tSnd0YUJROS11OVJGZUUxV19PQzNtX291b0hMQQ?oc=5","date":"2026-01-31","type":"pipeline","source":"AD HOC NEWS","summary":"The Truth About Dr. Reddy's Laboratories Ltd: Why Everyone Is Suddenly Watching This Pharma Player - AD HOC NEWS","headline":"The Truth About Dr. Reddy's Laboratories Ltd: Why Everyone Is Suddenly Watching This Pharma Player","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxONlh4UnlmWUM4TW8wN2wtcWl6cnJrQy1OcmxvUzlxVGdpQWNpUmdXNFVMX0pmUTc3dk5rXzU0WjNYSjRIZFZ2RUFhOUtPSW1fS3BTeVNUQnQ5QzZnMk9pUzFRTGFIWHBucFFUaUxEV3llN1Y1OWR3dXlSZExySlp4eERSbEYzQkprLW9EQXZzR09HMjdlTXhMb1JjTXFOOWVHamVaZ3duNTJsWDlwd1VWd0RDWnE0Zw?oc=5","date":"2026-01-16","type":"pipeline","source":"PMLiVE","summary":"From patients to consumers: why pharma communications must rethink the rules of engagement - PMLiVE","headline":"From patients to consumers: why pharma communications must rethink the rules of engagement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTFBTLW9QN2toUVFJeWJiUWxBZFg2cFgzM1o1ZmtjZlN6a193TDlJbjZJNXROXzNOODEtejNTUkhSYThWYm0wTVdwSFBsU25XOWtzSmZMaFZCMUFJODVCb2xhYTN4SEJHcnRUQ01TbjBMTk1sdml2NHl2Z2RIQWI?oc=5","date":"2025-05-13","type":"pipeline","source":"Al Día News","summary":"Trump vs. Big Pharma: The Price War Begins - Al Día News","headline":"Trump vs. Big Pharma: The Price War Begins - Al Día News","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxOWG05VE1pQ1hvcGxjeEh0cjVUWWZmYklZUjJJbldNZ1kyQVpaWnc0ZG1nZ05STk10TVFsUTBxMDFBZHdGZjR6cDE2NGFuNE5hRFZHNFdnOVNUQmFFVmlWU3ZhUzltRTZxdWRvRTloaUNheTEzbDNVWVVrZlB5NzU5M2I2NmtSY3BoWXJkY2tIYTlLeWF0d1NlUF9jUFI?oc=5","date":"2024-12-18","type":"pipeline","source":"European Medical Journal","summary":"Hook, line and sinker: Catching the attention of HCPs - European Medical Journal","headline":"Hook, line and sinker: Catching the attention of HCPs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE9VYkR4UDJaV2UyTzFHajdONHdhYkF5MVk4WHJxbEpKdVp1ckJtYXZKX2J2d0cyek9tUzZxNXgxcmtPbVNLTlpJWl9Mcl9sQ3lEdk1vbWRISW5rcmhIdjNHQlMwV2VqWFB6N1pZeVVB0gFyQVVfeXFMTjRDTWpqRFVUZF9Sa0ZKZDJ5N2piVlNBSVVCeWw2T09ENEVUT3hSaDYwVGV3UkVlamR4dnBoLWQ4T0RzdkRWbUNHekVaRThmZ2tQSDAzMTNFendQQTFuYWw4Z1B1LWRJbUFrTlYwUHlnMFVn?oc=5","date":"2022-09-16","type":"pipeline","source":"koreabiomed.com","summary":"Yuhan’s takeover of AtoGen draws the industry’s attention - koreabiomed.com","headline":"Yuhan’s takeover of AtoGen draws the industry’s attention","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTFA4cDI5MDIwc2tnUFp2UzgyelkzM2JHRFZjODdmM3ppSUZVb2JJMThPZFFnSk9BVHdDSzcyWnQxSmpLQzJlSF9jSkE0cWdaT2JTLVV1SDhkRDMwVHlUakdmLUFpNmIweGFuVWpNdkkwV1VfcE9UbTdYejV2SlptWHPSAYQBQVVfeXFMT0lGa1N0Z2pFd0JqeU9TcnVuWHVsNjh2Z2Vad0J4MGJKa3lpTWNsNGZfdzktcC1ZSVJOckFIU1RDVjFOTm5teGZwRGtCcTZJalBMOTg0VHoyaFN0VnFUUmlMdnZlNXZRQ2d0bVBkN3hUejFOUXdPM18weF8yVUFJbG10d01M?oc=5","date":"2014-09-25","type":"pipeline","source":"CNBC","summary":"Waksal brothers reunite in ImClone 2.0 - CNBC","headline":"Waksal brothers reunite in ImClone 2.0","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxPUy13TXEyb3BVNkZsb3dkLTB6SnJwQWdlYm5ybmZyUGtuWlhLNVpoNEpMTUR0TXZCZEstTVgwb2tCRXVRRHBNOF9mSWxfVktMamxmekxyZW5KaWdRdTdwTkdWYlpVNWZWdnU4cDBXUlRVY3FmVTQwSU9KNWZVX1F3WjB0MWV2c2t20gGOAUFVX3lxTFBVbkFES2dxaTd2ZkVlYmdSZXEyUmVGcXo4X0gwaU13YzRobk5ZVEtJeGU5Y1BwUlIyNEtFeFZQUG1kaFl4ZFBDQWZuNjZRaUhBMjlkMEJXSzc5UmN5VGtYRDloVktuaGhVNFBHdGJudU5lT0QtMkxfR24yNFQ4d1R4eHFkODhQcUkzU2hZS3c?oc=5","date":"2014-09-24","type":"pipeline","source":"CNBC","summary":"Banned ImClone founder plans IPO for new venture - CNBC","headline":"Banned ImClone founder plans IPO for new venture","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}